【摘要】 目的 了解成都市慢性丙型肝炎（简称丙肝）既往病例抗病毒治疗情况，分析影响病例接受抗病毒治疗的因素，为完善丙肝防治策略提供科学依据。方法 通过“中国疾病预防控制信息系统”导出2017—2022年成都市已终审的丙肝确诊病例，选取现住址为新都区、大邑县的病例资料，在患者知情同意下，进行问卷调查。调查内容包括一般人口学特征、医保参保情况、丙肝防治知识知晓情况和诊疗情况等。采用χ~2检验和多因素logistic回归模型分析丙肝患者抗病毒治疗的影响因素。结果 本研究发放334份有效问卷，回收有效问卷287份，有效回收率为85.9%。研究对象的丙肝防治知识知晓率为66.6%(191/287)，接受过抗病毒治疗的占74.9%(215/287)。多因素logistic回归分析结果显示，丙肝防治知识知晓（OR=5.905,95%CI:2.957～12.144）、既往有丙型肝炎病毒核糖核酸（hepatitis C virus ribonucleic acid,HCV RNA）检测史（OR=5.921,95%CI:3.021～11.782）的病例接受抗病毒治疗率较高。结论 成都市应进一步加强丙肝防治宣传教育力度，提高医疗卫生机构丙肝核酸检测能力，促进患者及时规范开展丙肝抗病毒治疗。更多还原

【Abstract】 Objective To investigate the status of antiviral treatment among chronic hepatitis C(HCV) cases in Chengdu and analyze factors influencing patients’ access to therapy, thereby providing a scientific basis for improving HCV prevention and treatment strategies. Methods Data on confirmed HCV cases reported in Chengdu from 2017 to 2022 were obtained from the Chengdu database of the Chinese Disease Prevention and Control Information System. Cases residing in Xindu district and Dayi county were included. A questionnaire survey was conducted with patients’ informed consent, collecting information on sociodemographic characteristics, health insurance status, awareness of HCV prevention and treatment, and treatment history. Factors associated with antiviral treatment were analyzed using the Chi-squared test and multivariable logistic regression. Results A total of 334 questionnaires were distributed, and 287 valid questionnaires were collected, with a valid response rate of 85. 9%. The awareness rate of HCV prevention and treatment among the study population was 66. 6%(191/287), and 74. 9%(215/287)had received antiviral treatment. Multivariate analysis showed that patients who were aware of HCV prevention and treatment(OR=5. 905, 95%CI:2. 957-12. 144) and those with a history of HCV-RNA testing(OR=5. 921, 95%CI:3. 021-11. 782) were more likely to have received antiviral treatment. Conclusion It is necessary to enhance public awareness of HCV prevention and treatment, expand the capacity for HCV RNA testing in healthcare facilities, and ensure timely and standardized delivery of antiviral therapy to HCV patients in Chengdu.更多还原